摘要
背景:胰腺癌管理仍然是社会面临的一个重大挑战。 不良预后导致化疗/放疗后患者存活率和生活质量下降。 虽然在药物开发方面已经取得了进展,用于靶向胰腺癌,但伴随药物抗性的问题使得它是徒劳的。 虽然常规饮食中水果和蔬菜的摄入与胰腺癌的风险降低有关,但是在胰腺癌临床试验中,多种天然药物被评估为与一线化疗药物组合的辅助治疗。 目的:本综述重点介绍了天然/膳食化合物作为新型抗癌药物的新发展领域; 这些是靶向多种途径的多效性试剂,在正常组织中毒性最小。 方法:我们采用了广泛的文献检索,并考虑了以简洁、均衡、结构化的格式提供的所有相关信息。 结果:用天然药物完成和进行中的人类研究显示出惊人的成功率,用于调节胰腺癌的发生。 合成、经批准的药物和天然药物的组合疗法不仅提高了患者的应答率,而且还有助于克服药物抗性并诱导对耐药肿瘤的化疗敏感性,而不是用于胰腺癌化学预防的单疗法。 结论:目前的综述主要集中在现有的化疗药物及其局限性,并继续探讨天然药物必须提供的化学预防剂的广泛领域。 它从广泛的文献分析中讨论了作用和可用信息的基础机制,以突出这些药物对胰腺癌的抗肿瘤作用的新颖性。
关键词: 胰腺癌,化疗药物,化学预防,天然/饮食药物,信号通路,药物候选。
Current Medicinal Chemistry
Title:Mechanisms and Drug Targets for Pancreatic Cancer Chemoprevention
Volume: 25 Issue: 22
关键词: 胰腺癌,化疗药物,化学预防,天然/饮食药物,信号通路,药物候选。
摘要: Background: Pancreatic cancer management remains a major challenge to society. Poor prognosis results in dismal patient survival rates and quality of life post chemo/radiation therapies. Although progress has been made in drug development for targeting pancreatic cancer, accompanying issues of drug resistance renders it futile. While intake of fruits and vegetables in routine diets has been linked to reduced risk of pancreatic cancer, a wide variety of natural agents are being evaluated as adjuvant therapies in combination with frontline chemotherapeutics in pancreatic cancer clinical trials.
Objective: This review highlights the emerging area of cancer chemoprevention with natural/ dietary compounds serving as novel agents possessing strong anticancer properties; these are pleiotropic agents targeting multiple pathways with minimal toxicity in normal tissue.
Methods: We employed extensive literature search and considered all the relevant information presented in a concise, well-balanced and structured format.
Results: Completed and ongoing human studies with natural agents have shown surprisingly successful rates for regulating pancreatic carcinogenesis. Combinatorial therapies with synthetic, approved drugs and natural agents not only improved the patient response rates, but also helped in overcoming drug resistance and inducing chemosensitivity to the resistant tumors, as opposed to monotherapies for pancreatic cancer chemoprevention.
Conclusion: The current review focuses on the available chemotherapeutic drugs and their limitations, and moves on to discuss the wide realm of chemopreventive efficacy that the natural agents have to offer. It discusses the underlying mechanisms of action and available information, from extensive literature analysis, to highlight the novelty of these agents for their antitumor effects against pancreatic cancer.
Export Options
About this article
Cite this article as:
Mechanisms and Drug Targets for Pancreatic Cancer Chemoprevention, Current Medicinal Chemistry 2018; 25 (22) . https://dx.doi.org/10.2174/0929867324666170320120647
DOI https://dx.doi.org/10.2174/0929867324666170320120647 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Anticancer Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Photothermal Ablation of Cancer Cells Using Folate-Coated Gold/ Graphene Oxide Composite
Current Drug Delivery Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment
Current Pharmaceutical Design Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Role of Moving Average Analysis for Development of Multi-Target (Q)SAR Models
Mini-Reviews in Medicinal Chemistry Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Gastric Carcinoma at the Era of Targeted Therapies
Current Drug Targets Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design GIST and Breast Cancer: 3 Case Reports and a Review of the Literature
Current Cancer Therapy Reviews STAT3: A Potential Drug Target for Tumor and Inflammation
Current Topics in Medicinal Chemistry Effect of Contrast-enhanced Contemporaneous <sup>18</sup>F-FDG PET/CT on Semi Quantification Uptake Value Using Third Party Viewing Workstation
Recent Patents on Medical Imaging Intracellular Restriction Factors In Mammalian Cells - An Ancient Defense System Finds A Modern Foe
Current HIV Research DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry LncRNA SNHG7 Serves as a Potential Biomarker on the Prognosis of Human Solid Tumors: A Meta-Analysis
Current Pharmaceutical Biotechnology